🔗 Share this article

The prestigious award in medical science was awarded for revolutionary discoveries that illuminate how the body's defense network targets dangerous infections while sparing the healthy tissues.

Three esteemed scientists—from Japan Prof. Sakaguchi and US scientists Dr. Brunkow and Fred Ramsdell—received this honor.

The work identified specialized "security guards" within the defense system that remove rogue defense cells capable of attacking the organism.

The discoveries are now enabling new therapies for autoimmune diseases and cancer.

These winners will divide a monetary award valued at 11m Swedish kronor.

Decisive Findings

"Their research has been decisive for comprehending how the immune system functions and why we do not all suffer from severe self-attack conditions," commented the head of the Nobel Committee.

The trio's studies address a fundamental question: In what way does the immune system protect us from numerous invaders while keeping our own tissues unharmed?

The immune system uses white blood cells that scan for signs of infection, including viruses and germs it has not met before.

These cells employ detectors—called receptors—that are generated by chance in a vast number of variations.

This gives the immune system the capacity to fight a wide array of threats, but the unpredictability of the process unavoidably creates immune cells that may target the host.

Protectors of the Immune System

Researchers previously knew that some of these problematic white blood cells were eliminated in the thymus—the site where immune cells mature.

This year's Nobel Prize recognizes the discovery of T-reg cells—described as the immune system's "security guards"—which travel through the system to disarm any defenders that assault the healthy cells.

We know that this process fails in self-attack conditions such as juvenile diabetes, MS, and rheumatoid arthritis.

The prize committee stated, "The discoveries have established a novel area of investigation and spurred the development of new therapies, for example for tumors and immune disorders."

In cancer, T-regs prevent the body from fighting the growth, so research are aimed at reducing their quantity.

For self-attack disorders, trials are testing boosting regulatory T-cells so the body is not under attack. A comparable approach could also be effective in minimizing the risks of organ transplant failure.

Innovative Studies

Professor Shimon Sakaguchi, from a Japanese institution, performed experiments on mice that had their thymus extracted, causing autoimmune disease.

He demonstrated that injecting defense cells from other animals could prevent the illness—suggesting there was a system for blocking defenders from harming the host.

Mary Brunkow, affiliated with the Institute for Systems Biology in Seattle, and Dr. Ramsdell, currently at Sonoma Biotherapeutics in a California city, were studying an genetic immune disorder in rodents and humans that led to the identification of a gene vital for the way regulatory T-cells function.

"The groundbreaking work has uncovered how the body's defenses is kept in check by regulatory T cells, stopping it from accidentally targeting the healthy cells," said a leading biological science specialist.

"This work is a striking illustration of how basic biological research can have far-reaching implications for human health."